Cargando…
Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
Direct Oral Anticoagulants (DOACs) , which partially replace warfarin, have been developed as a safe and effective therapy for patients with stable coronary artery disease (SCAD) and atrial fibrillation (AF). However, the choice of DOACs and warfarin remains controversial. We conducted a network met...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537486/ https://www.ncbi.nlm.nih.gov/pubmed/36198012 http://dx.doi.org/10.1177/10760296221131033 |
_version_ | 1784803211414077440 |
---|---|
author | Ma, Fang Yuan, Li Wen, Xinli Wang, Yangyang Li, Qiaofei Chen, Chu |
author_facet | Ma, Fang Yuan, Li Wen, Xinli Wang, Yangyang Li, Qiaofei Chen, Chu |
author_sort | Ma, Fang |
collection | PubMed |
description | Direct Oral Anticoagulants (DOACs) , which partially replace warfarin, have been developed as a safe and effective therapy for patients with stable coronary artery disease (SCAD) and atrial fibrillation (AF). However, the choice of DOACs and warfarin remains controversial. We conducted a network meta-analysis (NMA) using randomized controlled trials (RCTs) through a systematic literature review to evaluate the the efficacy and safety of DOACs in SCAD and AF patients. Five RCTs with 6524 patients were included. The results showed that patients taking DOACs had a lower risk of stroke/systemic embolism (OR, 0.64; 95% CI, 0.54-0.76, P < .00001, I(2) = 89%), intracranial bleeding (OR, 0.41; 95% CI, 0.26-0.64, P = .0001, I(2) = 0%), major bleeding (OR, 0.98; 95% CI, 0.81-1.148, P = .80, I(2) = 88%), and all-cause mortality (OR, 1.04; 95% CI, 0.88-1.22, P = .66, I(2) = 51%) than those taking warfarin. Compared to warfarin, rivaroxaban (20 mg, once/day) was more advantageous in preventing stroke/systemic embolism, as was apixaban (5 mg or 2.5 mg, twice/day) in reducing major bleeding (OR, 0.79; 95% CI, 0.48-1.3) and all-cause mortality (OR, 0.97; 95% CI, 0.69-1.4). Different doses of DOACs showed obvious advantages against intracranial hemorrhage, without significant differences. Thus, DOACs have more effective than warfarin in clinical efficacy and safety. |
format | Online Article Text |
id | pubmed-9537486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-95374862022-10-08 Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis Ma, Fang Yuan, Li Wen, Xinli Wang, Yangyang Li, Qiaofei Chen, Chu Clin Appl Thromb Hemost Original Manuscript Direct Oral Anticoagulants (DOACs) , which partially replace warfarin, have been developed as a safe and effective therapy for patients with stable coronary artery disease (SCAD) and atrial fibrillation (AF). However, the choice of DOACs and warfarin remains controversial. We conducted a network meta-analysis (NMA) using randomized controlled trials (RCTs) through a systematic literature review to evaluate the the efficacy and safety of DOACs in SCAD and AF patients. Five RCTs with 6524 patients were included. The results showed that patients taking DOACs had a lower risk of stroke/systemic embolism (OR, 0.64; 95% CI, 0.54-0.76, P < .00001, I(2) = 89%), intracranial bleeding (OR, 0.41; 95% CI, 0.26-0.64, P = .0001, I(2) = 0%), major bleeding (OR, 0.98; 95% CI, 0.81-1.148, P = .80, I(2) = 88%), and all-cause mortality (OR, 1.04; 95% CI, 0.88-1.22, P = .66, I(2) = 51%) than those taking warfarin. Compared to warfarin, rivaroxaban (20 mg, once/day) was more advantageous in preventing stroke/systemic embolism, as was apixaban (5 mg or 2.5 mg, twice/day) in reducing major bleeding (OR, 0.79; 95% CI, 0.48-1.3) and all-cause mortality (OR, 0.97; 95% CI, 0.69-1.4). Different doses of DOACs showed obvious advantages against intracranial hemorrhage, without significant differences. Thus, DOACs have more effective than warfarin in clinical efficacy and safety. SAGE Publications 2022-10-05 /pmc/articles/PMC9537486/ /pubmed/36198012 http://dx.doi.org/10.1177/10760296221131033 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Ma, Fang Yuan, Li Wen, Xinli Wang, Yangyang Li, Qiaofei Chen, Chu Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title | Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title_full | Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title_fullStr | Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title_full_unstemmed | Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title_short | Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis |
title_sort | efficacy and safety of direct oral anticoagulants in stable coronary artery disease and atrial fibrillation: a systematic review and network meta-analysis |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537486/ https://www.ncbi.nlm.nih.gov/pubmed/36198012 http://dx.doi.org/10.1177/10760296221131033 |
work_keys_str_mv | AT mafang efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis AT yuanli efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis AT wenxinli efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis AT wangyangyang efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis AT liqiaofei efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis AT chenchu efficacyandsafetyofdirectoralanticoagulantsinstablecoronaryarterydiseaseandatrialfibrillationasystematicreviewandnetworkmetaanalysis |